logo
Priority Technology Holdings, Inc. Reports Second Quarter Financial Results

Priority Technology Holdings, Inc. Reports Second Quarter Financial Results

Business Wire3 days ago
ALPHARETTA, Ga.--(BUSINESS WIRE)--Priority Technology Holdings, Inc. (NASDAQ: PRTH) ("Priority" or the "Company"), the payments and banking solution that streamlines collecting, storing, lending, and sending money to unlock revenue opportunities, today announced its second quarter 2025 financial results including strong year-over-year diversified revenue growth.
"Our strong second quarter results reflect the continued success of Priority's Connected Commerce platform, with over 9% revenue growth and 13% adjusted gross profit growth," said Tom Priore, Chairman & CEO of Priority. "Importantly, our ability to connect payments and banking solutions across our diverse business segments delivered over 30% growth in adjusted gross profit for B2B and over 20% growth in Enterprise, while adjusted gross profit from recurring revenue represents 62% of total. This strong momentum and high level of visibility gives us confidence to raise the low end of our full-year revenue guidance to $970 million and narrow our adjusted EBITDA guidance range to $222.5-$227.5 million. Priority is uniquely positioned to capitalize on the accelerating trend toward embedded finance as businesses increasingly seek comprehensive payment and banking solutions from a single platform.'
Highlights of Consolidated Results 1
Second Quarter 2025 Financial Highlights compared with Second Quarter 2024
Revenue of $239.8 million increased 9.1% from $219.9 million
Adjusted gross profit (a non-GAAP measure 2) of $92.4 million increased 13.0% from $81.7 million
Adjusted gross profit margin (a non-GAAP measure 2) of 38.5% increased 135 basis points from 37.2%
Operating income of $37.4 million increased 12.6% from $33.2 million
Adjusted EBITDA (a non-GAAP measure 2) of $56.0 million increased 8.7% from $51.6 million
Adjusted EPS (a non-GAAP measure 2) of $0.26 increased by $0.15, or 136.4%, from $0.11
(1)
Certain amounts/percentages may not compute accurately due to rounding.
(2)
See "Non-GAAP Financial Measures" and the reconciliations of Adjusted Gross Profit (non-GAAP), Adjusted Gross Profit Margin (non-GAAP), Adjusted EBITDA, and Adjusted EPS (non-GAAP) to their most comparable GAAP measures provided within this document for additional information.
Expand
Full Year 2025 Financial Guidance
Priority's outlook remains strong, and we are adjusting our full year 2025 guidance to reflect narrower ranges around the midpoint of our original full year guidance. We anticipate an acceleration of organic growth in the second half of 2025 based on timing of sales pipeline, the impact of year over year comparatives, and moderating headwinds in certain areas from the first half of 2025 that offset strong growth in core operating performance. The adjusted full year 2025 guidance is as follows:
Revenue forecast to range between $970 million to $990 million, a growth rate of 10.2% to 12.5%, compared to fiscal 2024 results. This ranges compares to original full year 2025 guidance of $965 million to $1 billion.
Adjusted gross profit (a non-GAAP measure) forecast to range between $365 million and $380 million, which compares to the original full year 2025 guidance range of $360 million to $385 million.
Adjusted EBITDA (a non-GAAP measure) forecast to range between $222.5 million to $227.5 million, which compares to the original full year 2025 guidance range of $220 million to $230 million.
Conference Call
The Company will host a conference call on Thursday, August 7, 2025 at 10:00 a.m. EDT to discuss its second quarter financial results. Participants can access the call by phone in the U.S. or Canada at (833) 636-1319 or internationally at (412) 902-4286.
The Internet webcast link and accompanying slide presentation can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1725531&tp_key=078fc7a00a and will also be posted in the "Investor Relations" section of the Company's website at www.prioritycommerce.com/investors.
An audio replay of the call will be available shortly after the conference call until August 21, 2025, at 11:59 p.m. EDT. To listen to the audio replay, dial (844) 512-2921 or (412) 317-6671 and enter conference ID number 10200777. Alternatively, you may access the webcast replay in the "Investor Relations" section of the Company's website at https://ir.prioritycommerce.com/.
Non-GAAP Financial Measures
This communication includes certain non-GAAP financial measures that we regularly review to evaluate our business and trends, measure our performance, prepare financial projections, allocate resources, and make strategic decisions. We believe these non-GAAP measures help to illustrate the underlying financial and business trends relating to our results of operations and comparability between current and prior periods. We also use these non-GAAP measures to establish and monitor operational goals. However, these non-GAAP measures are not superior to or a substitute for prominent measurements calculated in accordance with GAAP. Rather, the non-GAAP measures are meant to be a complement to understanding measures prepared in accordance with GAAP.
The Company's adjusted gross profit metric represents revenues less cost of revenue (excluding depreciation and amortization). Adjusted gross profit margin is adjusted gross profit divided by revenues. We review these non-GAAP measures to evaluate our underlying profit trends. The reconciliation of adjusted gross profit to its most comparable GAAP measure is provided below:
EBITDA and Adjusted EBITDA
EBITDA and adjusted EBITDA are performance measures. EBITDA is earnings before interest, income tax, and depreciation and amortization expenses ("EBITDA"). Adjusted EBITDA begins with EBITDA but further excludes certain non-cash costs, such as stock-based compensation and the write-off of the carrying value of investments or other assets, as well as debt extinguishment and modification expenses and other expenses and income items considered non-recurring, such as acquisition integration expenses, certain professional fees, and litigation settlements. We review the non-GAAP adjusted EBITDA measure to evaluate our business and trends, measure our performance, prepare financial projections, allocate resources, and make strategic decisions.
The reconciliation of adjusted EBITDA to its most comparable GAAP measure is provided below:
(in thousands)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Net income
$
10,879
$
994
$
19,147
$
6,187
Interest expense
23,054
21,710
46,230
42,590
Income tax expense
4,423
2,515
6,673
5,097
Depreciation and amortization
14,093
15,244
27,870
30,497
EBITDA
52,449
40,463
99,920
84,371
Debt modification and extinguishment expenses

8,623
38
8,623
Selling, general and administrative (non-recurring)
395
636
2,594
1,435
Non-cash stock-based compensation
3,206
1,829
4,792
3,462
Adjusted EBITDA
$
56,050
$
51,551
$
107,344
$
97,891
Expand
Further detail of certain of these adjustments, and where these items are recorded in our consolidated statements of operations, is provided below:
Adjusted Earnings Per Share (Adjusted EPS)
Adjusted EPS is a performance measure. Adjusted EPS is calculated by dividing adjusted net income (loss) attributable to common shareholders by weighted average number shares outstanding for the respective periods.
Adjusted net income attributable to common shareholders begins with net income (loss) attributable to common shareholders adjusted to exclude various items listed below. We believe that adjusted EPS is a measure that is useful to investors and management in understanding our ongoing profitability and in analysis of ongoing profitability trends.
Priority does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, stock-based compensation expense would be difficult to estimate because it depends on the Company's future hiring and retention needs, as well as the future fair market value of the Company's common stock, all of which are difficult to predict and subject to constant change. As a result, the Company does not believe that a GAAP reconciliation would provide meaningful supplemental information about the Company's outlook.
About Priority Technology Holdings, Inc.
Priority is the payments and banking solution that enables businesses to collect, store, lend and send funds through a unified commerce engine. Our platform combines payables, merchant services, and banking and treasury solutions so leaders can streamline financial operations efficiently — and our innovative industry experts help businesses navigate and build momentum on the path to growth. With the Priority Commerce Engine, leaders can accelerate cash flow, optimize working capital, reduce unnecessary costs, and unlock new revenue opportunities. To learn more about Priority (NASDAQ: PRTH), visit prioritycommerce.com
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services, and other statements identified by words such as "may," "will," "should," "anticipates," "believes," "expects," "plans," "future," "intends," "could," "estimate," "predict," "projects," "targeting," "potential" or "contingent," "guidance," "outlook" or words of similar meaning. These forward-looking statements include, but are not limited to, our 2025 outlook and statements regarding our market and growth opportunities. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive risks, trends and uncertainties that could cause actual results to differ materially from those projected, expressed, or implied by such forward-looking statements. Our actual results could differ materially, and potentially adversely, from those discussed or implied herein.
We caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this press release in the context of the risks and uncertainties disclosed in our SEC filings, including our most recent Annual Report on Form 10-K filed with the SEC on March 6, 2025. These filings are available online at www.sec.gov or www.prioritycommerce.com.
We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.
Priority Technology Holdings, Inc.
Unaudited Consolidated Balance Sheets
(in thousands)
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$
50,564
$
58,600
Restricted cash
14,205
11,090
Accounts receivable, net of allowances
86,029
67,969
Prepaid expenses and other current assets
25,870
22,990
Current portion of notes receivable, net of allowance
3,283
3,638
Settlement assets
1,125,934
940,798
Total current assets
1,305,885
1,105,085
Notes receivable, less current portion
6,704
4,919
Property, equipment and software, net
57,529
52,477
Goodwill
382,497
376,091
Intangible assets, net
225,035
240,874
Deferred income taxes, net
27,015
24,697
Other noncurrent assets
22,755
22,717
Total assets
$
2,027,420
1,826,860
Liabilities, Stockholders' Deficit and NCI
Current liabilities:
Accounts payable and accrued expenses
$
53,692
$
62,149
Accrued residual commissions
40,526
37,560
Customer deposits and advance payments
3,433
2,246
Current portion of long-term debt
4,254
9,503
Settlement obligations
1,127,266
940,213
Total current liabilities
1,229,171
1,051,671
Long-term debt, net of current portion, discounts and debt issuance costs
917,017
920,888
Other noncurrent liabilities
25,366
19,326
Total liabilities
2,171,554
1,991,885
Stockholders' deficit:
Preferred stock


Common stock
80
77
Treasury stock, at cost
(21,921
)
(19,607
)
Additional paid-in capital
3,629

Accumulated other comprehensive loss
84
(176
)
Accumulated deficit
(127,987
)
(147,134
)
Total stockholders' deficit attributable to stockholders of Priority
(146,115
)
(166,840
)
Non-controlling interests in consolidated subsidiaries
1,981
1,815
Total stockholders' deficit
(144,134
)
(165,025
)
Total liabilities, stockholders' deficit and NCI
$
2,027,420
$
1,826,860
Expand
Priority Technology Holdings, Inc.
Unaudited Consolidated Statements of Cash Flows
(in thousands)
Six Months Ended June 30,
2025
2024
Cash flows from operating activities:
Net income
$
19,147
$
6,187
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of assets
27,870
30,497
Stock-based, ESPP and incentive units compensation
4,792
3,462
Amortization of debt issuance costs and discounts
882
1,824
Debt extinguishment and modification costs
38
8,623
Deferred income tax
(2,318
)
(3,023
)
Change in deferred consideration
2,039
2,213
Other non-cash items, net
(228
)
(929
)
Change in operating assets and liabilities:
Accounts receivable
(17,912
)
(7,145
)
Prepaid expenses and other current assets
(2,312
)
(1,148
)
Income taxes (receivable) payable
(339
)
(5,037
)
Notes receivable

(584
)
Accounts payable and accrued expenses
(6,810
)
10,225
Accrued residuals commissions
2,966
3,066
Customer deposits and advance payments
1,187
(365
)
Other noncurrent assets and liabilities, net
(1,922
)
(5,859
)
Net cash provided by operating activities
27,080
42,007
Cash flows from investing activities:
Acquisition of business, net of cash acquired
(4,452
)

Additions to property, equipment and software
(12,988
)
(11,718
)
Notes receivable, net
(1,430
)
(1,406
)
Acquisitions of assets and other investing activities
(2,275
)
(7,474
)
Net cash used in investing activities
(21,145
)
(20,598
)
Cash flows from financing activities:
Proceeds from issuance of long-term debt, net of issue discount

830,200
Debt issuance and modification costs paid
(40
)
(7,555
)
Repayments of long-term debt
(10,000
)
(654,372
)
Redemption of PHOT redeemable NCI

(2,130
)
Repurchases of shares withheld for taxes
(2,314
)
(604
)
Redemption of senior preferred stock

(136,936
)
Redemption of accumulated unpaid dividend on redeemable senior preferred stock

(30,819
)
Dividends paid to redeemable senior preferred stockholders

(16,393
)
Proceeds from exercise of stock options
334

Settlement obligations, net
190,863
40,914
Payment of deferred/contingent consideration related to business combination
(752
)
(4,156
)
Net cash provided by financing activities
178,091
18,149
Net change in cash and cash equivalents and restricted cash:
Net increase in cash and cash equivalents, and restricted cash
184,026
39,558
Cash and cash equivalents and restricted cash at beginning of period
993,864
796,223
Reconciliation of cash and cash equivalents, and restricted cash:
Cash and cash equivalents
$
50,564
$
34,626
Restricted cash
14,205
12,625
Cash and cash equivalents included in settlement assets (restricted in nature)
1,113,121
788,530
Total cash and cash equivalents, and restricted cash
$
1,177,890
$
835,781
Expand
Expand
Six Months Ended June 30, 2025
SMB
Payments
B2B
Payments
Enterprise
Payments
Corporate
Total
Consolidated
Reconciliation of Adjusted EBITDA to GAAP Measure:
Adjusted EBITDA
$
53,454
$
7,286
$
88,001
$
(41,397
)
$
107,344
Interest expense

(1,796
)
(243
)
(44,191
)
(46,230
)
Depreciation and amortization
(13,258
)
(2,523
)
(9,583
)
(2,506
)
(27,870
)
Debt modification and extinguishment expenses



(38
)
(38
)
Selling, general and administrative (non-recurring)



(2,594
)
(2,594
)
Non-cash stock based compensation
1
(168
)
(65
)
(4,560
)
(4,792
)
Income (loss) before taxes
$
40,197
$
2,799
$
78,110
$
(95,286
)
$
25,820
Income tax expense
(6,673
)
Net income
$
19,147
Expand
Three Months Ended June 30, 2024
Reconciliation of Adjusted EBITDA to GAAP Measure:
Adjusted EBITDA
$
28,597
$
1,530
$
37,244
$
(15,820
)
$
51,551
Interest expense

(1,241
)

(20,469
)
(21,710
)
Depreciation and amortization
(8,541
)
(1,261
)
(4,087
)
(1,355
)
(15,244
)
Debt modification and extinguishment expenses



(8,623
)
(8,623
)
Selling, general and administrative (non-recurring)



(636
)
(636
)
Non-cash stock based compensation
(4
)
(109
)
(32
)
(1,684
)
(1,829
)
Income (loss) before taxes
$
20,052
$
(1,081
)
$
33,125
$
(48,587
)
$
3,509
Income tax expense
(2,515
)
Net income
$
994
Expand
Six Months Ended June 30, 2024
SMB
Payments
B2B
Payments
Enterprise
Payments
Corporate
Total
Consolidated
Reconciliation of Adjusted EBITDA to GAAP Measure:
Adjusted EBITDA
$
53,620
$
3,276
$
71,971
$
(30,976
)
$
97,891
Interest expense

(2,214
)

(40,376
)
(42,590
)
Depreciation and amortization
(17,127
)
(2,731
)
(8,126
)
(2,513
)
(30,497
)
Debt modification and extinguishment expenses



(8,623
)
(8,623
)
Selling, general and administrative (non-recurring)



(1,435
)
(1,435
)
Non-cash stock based compensation
(8
)
(227
)
(65
)
(3,162
)
(3,462
)
Income (loss) before taxes
$
36,485
$
(1,896
)
$
63,780
$
(87,085
)
$
11,284
Income tax expense
(5,097
)
Net income
$
6,187
Expand
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now?
If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now?

Yahoo

timean hour ago

  • Yahoo

If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Micron Technology Inc. (NASDAQ:MU) designs, develops, manufactures, and sells memory and storage products globally. It is set to report its Q4 2025 earnings on Sept. 24. Wall Street analysts expect the company to post EPS of $2.51, up from $1.18 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $10.73 billion, up from $7.75 billion a year earlier. Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. If You Bought Micron Technology Stock 10 Years Ago The company's stock traded at approximately $18.91 per share 10 years ago. If you had invested $10,000, you could have bought roughly 529 shares. Currently, shares trade at $108.16, meaning your investment's value could have grown to $57,197 from stock price appreciation alone. However, Micron Technology also paid dividends during these 10 years. Micron Technology's dividend yield is currently 0.43%. Over the last 10 years, it has paid about $1.79 in dividends per share, which means you could have made $947 from dividends alone. Summing up $57,197 and $947, we end up with the final value of your investment, which is $58,144. This is how much you could have made if you had invested $10,000 in Micron Technology stock 10 years ago. This means a total return of 481.44%. In comparison, the S&P 500 total return for the same period is 258.20%. Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— What Could The Next 10 Years Bring? Micron Technology has a consensus rating of "Buy" and a price target of $149.07 based on the ratings of 28 analysts. The price target implies more than 37% potential upside from the current stock price. The company on June 25 announced its Q3 2025 earnings, posting revenues of $9.3 billion, beating the consensus estimate of $8.87 billion. The company reported adjusted EPS of $1.91, above the consensus of $1.60. Micron expects Q4 revenue of $10.7 billion, plus or minus $300 million, versus estimates of $9.88 billion. Adjusted EPS is expected to be $2.50, plus or minus $0.15, versus the consensus of $2.01 per out this article by Benzinga for P/E ratio insights for Micron Technology. Given the historical stock price appreciation and expected upside potential, growth-focused investors may find Micron Technology stock attractive. Furthermore, they can benefit from the company's modest dividend yield of 0.43%. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's , starting article If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Iovance Biotherapeutics Stock Plummeted Today
Why Iovance Biotherapeutics Stock Plummeted Today

Yahoo

time2 hours ago

  • Yahoo

Why Iovance Biotherapeutics Stock Plummeted Today

Key Points Investors were hardly pleased by the company's double miss on second-quarter results. At least its revenue guidance was in line with expectations. 10 stocks we like better than Iovance Biotherapeutics › Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (NASDAQ: IOVA). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%. Amtagvi leads the way Iovance, a commercial-stage biotech that's focused on cell therapies for cancer treatment, reported slightly under $60 million in revenue for the period, which was nearly double the $31 million it earned in the same quarter of 2024. All of this is derived from sales of two products: Amtagvi and Proleukin. The former was by far the company's star, with over $54 million in sales. The steep increase in sales didn't filter down into a net profit, however. In fact, Iovance's GAAP (generally accepted accounting principles) net loss deepened during the quarter, coming in at almost $112 million ($0.33 per share) from the year-ago deficit of $97 million. Also, analysts were expecting Iovance to boost its top line even more. Their consensus estimate for revenue was a shade over $67 million. As for net loss, they were modeling a deficit of only $0.28 per share. In its earnings release, Iovance nevertheless sounded a bullish note about the future of its two commercialized products. It quoted CEO Frederick Vogt as saying that "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing authorized treatment center growth continues and large community practices begin treating patients." No move on revenue guidance Investors might have liked to see that statement bolstered by a guidance raise. However, Iovance stuck to its existing forecast of $250 million to $300 million anchored, of course, by Amtagvi. The company pointed out that this is the first full year of Amtagvi sales, implying the future should be much rosier for the product. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Plummeted Today was originally published by The Motley Fool Sign in to access your portfolio

Why Nektar Therapeutics Stock Popped 6% on Friday
Why Nektar Therapeutics Stock Popped 6% on Friday

Yahoo

time3 hours ago

  • Yahoo

Why Nektar Therapeutics Stock Popped 6% on Friday

Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store